Related Experiment Video
Updated: May 17, 2025
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Successful treatment of localized scleroderma using brodalumab: A case report
Alexandra Carla Bobica1, Catherine Zhu2, Catherine Silotch1
1Division of Clinical and Translational Research, McGill University, Montreal, QC, Canada.
Brodalumab, an IL-17 receptor antagonist, effectively treated severe localized scleroderma resistant to standard treatments. This suggests IL-17 pathway blockade may be a promising therapy for autoimmune fibrotic conditions.
Area of Science:
- Immunodermatology
- Rheumatology
- Fibrotic Diseases
Background:
- Localized scleroderma is a chronic autoimmune fibrotic condition with limited treatment options.
- Conventional therapies like methotrexate, mycophenolate mofetil, and corticosteroids are often insufficient for severe cases.
- The role of IL-17 signaling in the pathogenesis of localized scleroderma is not fully understood.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
14:49Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration
Published on: September 29, 2018